Creatv provides liquid biopsy tests for a spectrum of clinical applications for solid tumors: (1) screen for one or multiple cancers, (2) provide companion diagnostics, (3) predict treatment response within 60 days, (4) provide prognosis, (5) deliver many copies of tumor DNA, (6) detect residual disease, and (7) early detection of recurrence. This is personalized medicine based on cancer-associated stromal cells and circulating tumor cells collected from the blood.